dc.contributor.author | Bernabe, Rosemarie de la Cruz | |
dc.contributor.author | Torres, Cristina E. | |
dc.contributor.author | Wangge, Grace | |
dc.contributor.author | Jimenez, Edlyn B. | |
dc.contributor.author | Karbwang, Juntra | |
dc.date.accessioned | 2022-05-27T10:06:53Z | |
dc.date.available | 2022-05-27T10:06:53Z | |
dc.date.created | 2022-02-03T19:16:02Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Bernabe, R., Torres, C., Wangge, G., Jimenez, E. & Karbwang, J. (2022). Regulatory oversight on the use of experimental therapies during a pandemic: The case of early access to convalescent plasma therapy in three LMICs. Drug Discovery Today, 27(3), 686-689. | en_US |
dc.identifier.issn | 1359-6446 | |
dc.identifier.uri | https://hdl.handle.net/11250/2996397 | |
dc.description.abstract | Clinicians, especially in low- and middle-income countries (LMICs), contend with limited economic and healthcare resources in deciding appropriate and feasible care for their patients. Some of the LMICs affected by COVID-19 implemented convalescent plasma therapy without sufficient regulatory guidance. Based on this experience, there are several requirements going forward, including: the need for an immediately accessible data gathering and processing system; the necessity of establishing regulatory pathways for early access to experimental treatment during emergency situations; and the accompanying reporting and monitoring requirements must be set. The different stakeholders must also be properly incorporated in the system that such a pathway will create, without neglecting to properly inform the public of the patient rights especially during an emergency situation. | en_US |
dc.language.iso | eng | en_US |
dc.relation.uri | https://www.sciencedirect.com/science/article/pii/S1359644621005365 | |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | Regulatory oversight on the use of experimental therapies during a pandemic: The case of early access to convalescent plasma therapy in three LMICs | en_US |
dc.type | Peer reviewed | en_US |
dc.type | Journal article | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | © 2021 The Author(s). | en_US |
dc.source.pagenumber | 686-689 | en_US |
dc.source.volume | 27 | en_US |
dc.source.journal | Drug Discovery Today | en_US |
dc.source.issue | 3 | en_US |
dc.identifier.doi | https://doi.org/10.1016/j.drudis.2021.12.002 | |
dc.identifier.cristin | 1997599 | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |